GreenLight Biosciences Holdings, PBC Common Stock
GRNA
GRNA was delisted on the 21st of July, 2023.
50 hedge funds and large institutions have $65.2M invested in GreenLight Biosciences Holdings, PBC Common Stock in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 12 closing their positions.
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
28% more funds holding
Funds holding: 39 → 50 (+11)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
77% less capital invested
Capital invested by funds: $280M → $65.2M (-$215M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.61M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$1.73M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.33M |
| 4 |
Swiss National Bank
Zurich,
Switzerland
|
+$803K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$773K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCMH
Oxbow Capital Management (HK)
Hong Kong
|
-$4.64M |
| 2 |
PVI
Pura Vida Investments
New York
|
-$3.85M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.81M |
| 4 |
Jane Street
New York
|
-$686K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$604K |
GRNA Hedge Fund Activity: Q2 2022 in Review
50 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in GreenLight Biosciences Holdings, PBC Common Stock (GRNA) for Q2 2022, worth a combined $65.2M — down 77% from $280M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new GRNA positions and 12 closed out — a net gain of 12 holders — while 13 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $4.61M. The largest seller was Oxbow Capital Management (HK), exiting entirely with an estimated $4.64M sold.
- 50 institutional investors held GreenLight Biosciences Holdings, PBC Common Stock (GRNA) as of Q2 2022, up from 39 in Q1 2022.
- Funds reported $65.2M of GreenLight Biosciences Holdings, PBC Common Stock stock for Q2 2022, down 77% quarter-over-quarter.
- 24 funds opened new GreenLight Biosciences Holdings, PBC Common Stock positions in Q2 2022 and 12 closed out, a net change of +12 holders.
- The largest GreenLight Biosciences Holdings, PBC Common Stock buyer in Q2 2022 was BlackRock, an estimated $4.61M added.
- The largest GreenLight Biosciences Holdings, PBC Common Stock seller in Q2 2022 was Oxbow Capital Management (HK), an estimated $4.64M sold.
Based on aggregated 13F filings for Q2 2022.